Recursion (RXRX) Director Receives 2,941 Shares via Compensation

Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), reported acquiring 2,941 shares of Class A common stock on 10/01/2025.

Rhea-AI Filing Summary

Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), reported acquiring 2,941 shares of Class A common stock on 10/01/2025. The shares were issued $0 under the issuer's Outside Director Compensation Policy. After the transaction, the reporting person beneficially owned 138,758 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. This filing discloses routine director compensation in equity form.

Positive

• 2,941 shares issued to a director under the Outside Director Compensation Policy
• Transaction reflects alignment of director incentives with shareholders via equity compensation

Negative

• None.

Insights

Corporate Governance Expert

Director received equity pay: 2,941 shares issued under compensation policy.

This filing documents a non-cash grant to a director under the company's outside director compensation plan, indicating standard governance practice for aligning director incentives with shareholders.

The reporting shows 138,758 shares held after the award, which provides context on the director's stake but does not by itself signal a material change to control or ownership.

Insider Trade Summary

Grant/Award: 2,941 shares

Grant/Award 1 txn

Insider Dar Zavain

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	2,941	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 138,758 shares (Direct)

Footnotes (1)

1. F1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

FAQ

What transaction did Dar Zavain report on Form 4 for RXRX?

Acquisition of 2,941 Class A common shares reported on 10/01/2025, issued under the issuer's outside director compensation policy.

How many RXRX shares does the reporting person beneficially own after the transaction?

138,758 shares beneficially owned following the reported transaction.

What price was reported for the shares acquired by the director?

The shares were issued at a reported price of $0 under the compensation policy.

Was the Form 4 filing signed and when?

The filing shows a signature by an attorney-in-fact dated 10/03/2025.

Under what policy were the shares issued?

The shares were issued pursuant to the issuer's Outside Director Compensation Policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dar Zavain

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2025		A(1)		2,941	A	$0	138,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.